Deficiency of STING Promotes Collagen-Specific Antibody Production and B Cell Survival in Collagen-Induced Arthritis by Tansakul, Mookmanee et al.
ORIGINAL RESEARCH
published: 03 June 2020
doi: 10.3389/fimmu.2020.01101















This article was submitted to
Autoimmune and Autoinflammatory
Disorders,
a section of the journal
Frontiers in Immunology
Received: 16 December 2019
Accepted: 06 May 2020
Published: 03 June 2020
Citation:
Tansakul M, Thim-uam A, Saethang T,
Makjaroen J, Wongprom B, Pisitkun T
and Pisitkun P (2020) Deficiency of
STING Promotes Collagen-Specific
Antibody Production and B Cell
Survival in Collagen-Induced Arthritis.
Front. Immunol. 11:1101.
doi: 10.3389/fimmu.2020.01101
Deficiency of STING Promotes
Collagen-Specific Antibody
Production and B Cell Survival in
Collagen-Induced Arthritis
Mookmanee Tansakul 1, Arthid Thim-uam 2, Thammakorn Saethang 2, Jiradej Makjaroen 2,
Benjawan Wongprom 2, Trairak Pisitkun 2 and Prapaporn Pisitkun 1,3*
1 Section for Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand,
2Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 3Division of
Allergy, Immunology, and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand
The levels of interferon-alpha are high in the serum and synovial fluid of rheumatoid
arthritis (RA) patients. Activation of the stimulator of type I interferon genes (STING)
mediates the productions of type I interferon and promotes chronic inflammation. STING
plays a significant role in autoimmune lupus mice. However, the function of STING in
collagen-induced arthritis (CIA) model has never been described. This study aimed to test
the function of STING in CIA. The Sting-deficient mice developed arthritis comparable to
WT mice. The levels of anti-collagen antibody from Sting-deficient mice were significantly
higher than the WT mice. The B cells derived from Sting-deficient mice showed better
survival than WT mice in response to the B cell receptor (BCR) stimulation. Activation of
STING also induced B cell death, especially in activated B cells. This study demonstrated
that the inhibition of STING promotes anti-collagen antibodies and B cell survival, which
suggested that STING acts as a negative regulator of B cell function in the CIA model.
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INTRODUCTION
RA is a chronic systemic autoimmune disease that directly causes damage to the joints and
cartilages and also induces inflammation throughout the body, such as the lung, eye, and
cardiovascular system (1). The etiology of RA is unclear, and the response to the treatment is varied,
which depends on numerous factors. The production of autoantibody against cartilage and joint
could promote bone erosion and synovial hyperplasia (2, 3). Although several biologic drugs are
available, not all patients can achieve remission or low disease activity (4). The successful treatment
will prevent disability and improve the quality of life in RA patients.
The pathogenesis of rheumatoid arthritis (RA) is complicated and involves both innate and
adaptive immunity (5). The synovium of RA contains two special cell types (fibroblast-like
synoviocytes (FLS) and macrophage-like synoviocytes), which are part of innate immunity. These
synoviocytes generate inflammatory mediators, including TNF-α, IL-1, IL-6, IL-17, IFN-γ, and
chemokines that lead to synovial inflammation, bone erosion, and cartilage damage (6–8). The IL-
17 signaling mediates the autoantibody production in the collagen-induced arthritis (CIA) model
(9). However, the treatment response with an anti-IL17 monoclonal antibody in RA patients shows
Tansakul et al. STING Deficiency Promotes B-Cell Survival
a high degree of heterogeneity (10). The inhibitors of the Janus
kinase (JAK) pathway are approved for RA patients (11). These
data suggest that the targeted multiple cytokines through the JAK
pathway are useful for RA treatment.
Disturbance of type I IFNs (IFNs-I) signaling and production
drive autoimmune development (12). The presymptomatic RA
patients display an increase of IFNs-I before the onset of
symptoms (13). The RA patients also show the elevation of
IFN- α in the synovial fluid and high expression of IFNs-I
regulated gene in peripheral blood mononuclear cells (PBMC)
(14). However, the role of IFNs-I in arthritis and bone
homeostasis has suggested the accelerating effect of arthritis
and bone damage. The interferon-alpha receptor knockout
mice develop arthritis severity higher than wild-type mice
in the model of antigen-induced arthritis (15). IFNs-I also
affects the bone homeostasis by inhibiting osteoclastogenesis
via receptor activator of nuclear factor-kappa B (RANK)
pathway, and reduction of c-FOS expression (16–18). Therefore,
the goal of RA treatment with antagonizing the IFNs-I
pathway has to be optimized between efficacy and potentially
adverse effect.
STING is a cytosolic DNA sensor that initiates the
production of IFNs-I. STING functions have been reported
as both pro-inflammatory signaling and negative regulator
against inflammation (19–21). The mutation in exon
5 of the STING gene results in gain function, leading
to initiate inflammation, and cause the Sting associated
vasculopathy with onset in infancy (SAVI) (22). Loss of
STING function rescues DNaseII-deficient mice from lethality
and polyarthritis (23). However, Sting-deficient lupus mice
(MRL/Lpr mice) show higher and earlier mortality than
Sting-sufficient MRL/Lpr mice. The Sting-sufficient MRL/Lpr
mice showed an increase of lymphoid hypertrophy with
inflammatory cell infiltration, autoantibodies, and cytokine
production (24).
The objective of this study was to identify the role of STING
in the pathogenesis of rheumatoid arthritis using collagen-




The Stinggt/gt mice were provided from Professor Paludan
(Aarhus University, Denmark), while wild-type mice were
purchased from the National Laboratory Animal Center,
Nakornpathom, Thailand. The Stinggt/gt is also known as
the golden ticket (Tmem173gt) mice. Stinggt/gt was created
via chemically inducing mutagen with N-ethyl-N-nitrosourea
(ENU) in the C57BL/6 background. The Stinggt/gt mice carry
a single nucleotide variant (T596A) of Sting, which led to
undetectable STING protein by western blot (25). Mice were bred
and housed in the facility at Faculty of Medicine, Chulalongkorn
University, and all experiments were performed with the
approval of the Animal Experimentation Ethics Committee
of Chulalongkorn University Medical School with all relevant
institutional guidelines.
Collagen-Induced Arthritis (CIA) Model
The model was performed as previously described (26). CIA
was induced in the mice at the age between 10 and 14 weeks.
The immunization grade chick CII (2 mg/ml; #20012; Chondrex,
Redmond, WA) was mixed gently with an equal volume of a
4 mg/ml Freund’s complete adjuvant (CFA) (# 7001; Chondrex,
Redmond, WA). Mice were anesthetized by isoflurane, and then
intradermal injection was performed at multiple sites on the base
of a tail (<50 µl/site). Experimental mice received 150 µl of
CFA + CII emulsion, and control mice received only CFA or
PBS. Three weeks after the first injection, mice received a booster
injection of CFA + CII emulsion, CFA alone, or PBS. The mice
were monitored and graded for arthritis severity (0 = normal; 1
= slight swelling and/or erythema; 2= pronounced swelling; 3=
ankyloses) while performing the blind technique every other day.
Detection of Anti-collagen Type 2 Specific
Antibody
Chick collagen type 2 ELISA grade (#2011; Chondrex Redmond,
WA) was coated on the plate overnight at 4◦C. The plates were
washed with 0.05% Tween-20 in PBS and then blocked with
2% BSA, 0.1% Tween-20 in PBS for 1 h at room temperature
(RT). Then the plates were washed, added with the diluted
serum, and incubated at 37◦C for 1 h. Next, the plates were
washed and added with antibodies to IgG (#115-035-146; Jackson
ImmunoResearch Laboratories, PA, USA), IgG2b, IgG2c, or
IgM conjugated with HRP (#1091-05, #1078-05 and #1021-
05, respectively; SouthernBiotech, Birmingham, AL) were added
and incubated for 1 h at 37◦C. The plates were washed, added
with OPD peroxidase substrate (Sigma-Aldrich, Darmstadt,
Germany), and stopped reaction with 2NH2SO4. The absorbance
was measured at 492 nm using the Varioskan Flash Microplate
Reader (Thermo Fisher Scientific, MA USA).
The standard plate was coated with Goat Anti-Mouse IgM,
IgG, IgG2b, or IgG2c (#115-005-075, #115-005-146, #115-005-
207 and #115-005-208, respectively; Jackson ImmunoResearch
Laboratories, PA USA) and then serial dilutions of IgG (#015-
000-003; Jackson ImmunoResearch Laboratories, PA, USA),
IgG2b, IgG2c, or IgM (#0104-01, #0122-01 and #0101-01,
respectively; Southern Biotech, Birmingham, AL) were added to
obtain a standard linear curve. The intra-assay CV of ELISA
testing for each of immunoglobulin isotypes is ranging from 3.74
to 6.97%.
Histopathology
Mice were sacrificed 3 weeks after booster injection. Paws
were fixed with 10% formalin, then decalcified with 10%
ethylenediaminetetracetic acid (EDTA). The tissues were
embedded in paraffin, sectioned, and stained with Haematoxylin
and Eosin (H&E). The paw sections were viewed and captured
under the Nikon Eclipse Ti-U microscope. Histology scores
were graded and characterized by cell infiltration, synovial
hyperplasia, and bone erosion (27). The qualitative scoring was
evaluated with a blind technique.
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Flow Cytometry Analysis
Then the cell suspension was washed and stained for 15min with
antibodies as follows: B220 (RA3-6B2), CD3e (145-2C11), CD4
(GK1.5), CD45RB (C363-16A), CD11c (N418), CD11b (M1/70),
CD95 (15A7), CD80 (16-10A1), and viability dye eFluor780
(Biolegend, San Diego, CA, USA). The stained cells were washed
with 0.5% BSA in PBS and fixed with 1% paraformaldehyde
in PBS. Sera from mice were collected at 3 weeks following
the first immunization. Serum cytokines were measured by
the LEGENDplexTM mouse inflammation panel kit (#740446;
Biolegend, San Diego, CA, USA). Flow cytometry was performed
using BDTM LSR-II (BD Biosciences, USA) and analyzed by
FlowJo software (version 10, USA) and LEGENDplexTM Data
Analysis Software.
Single-Cell Isolation and B Cell Purification
Spleens and inguinal lymph nodes were collected. Every single
cell was isolated by pressing spleens or lymph nodes through a
cell strainer in cold 0.5% BSA in PBS solution. Red blood cells
were lysed by adding cold ACK lysis buffer for 5min. The cell
suspension was washed and resuspended in 0.5% BSA in PBS.
B cells were isolated from splenocytes by negative with anti-
CD43 (Ly-48), which follows the protocol from the manufacturer
(Miltenyi, Bergisch Gladbach, Germany).
Microarray Analysis
RNA was isolated with Trizol reagent (Invitrogen, CA, USA)
and followed by the RNeasy mini kit from Qiagen, MD, USA
(catalog no. 74104). The RNA was labeled and hybridized
using the Agilent One-Color Microarray-Based Gene Expression
Analysis protocol (Agilent Technology, V 6.5, 2010). The
results of the microarray were extracted with Agilent Feature
Extraction software v11.0 (Agilent Technologies, Palo Alto,
USA). We classified the gene function by using the online
resource Database for Annotation, Visualization, and Integrated
Discovery (DAVID, v6.8, https://david.ncifcrf.gov/), Interferome
(http://www.interferome.org) and Reactome (https://reactome.
org/) Microarray data was shown in the link below https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142624.
Proteomic Analysis
Dimethyl labeling and LC-MS/MS analysis were performed as
described in Makjaroen et al. (28). In brief, B cells were isolated
from Stinggt/gt andWTmice after injection with CFA andCII for
3 weeks. Isolated B cells were lysed with 5 %sodium deoxycholate
(SDC) Thermo Fisher Scientific, MA USA) and trypsinized.
Peptide 300µg ofWT and Stinggt/gt mice were labeled with light
reagents) formaldehyde and cyanoborohydride) and medium
reagents) formaldehyde-d2 and cyanoborohydride, respectively.
The labeled peptides were pooled and fractionated into eight
fractions before analysis with MS. The protein must be identified
at least three samples from each group to qualify for further
bioinformatics analysis. Peak intensity was calculated in log2
ratios L/M) and compared against a value of 0) no change,
log2. Proteome DiscovererTM ver. 2.1 and MAXQUANTTM ver.
1.4.1.0 software was employed to quantify the relative MS signal
intensities of dimethyl labeled-peptides. We classified the protein
function by using the online resource Database for Annotation,
Visualization, and Integrated Discovery DAVID, v6.8, https://
david.ncifcrf.gov/ and Reactome https://reactome.org/. (The
mass spectrometry proteomics data, including annotated spectra
for all modified peptides and proteins identified based on a
single peptide, have been deposited to the ProteomeXchange
Consortium via the Proteomics IDEntifications PRIDE) partner
repository with the data set identifier PXD018652.
In vitro Stimulation Assay
In brief, B cells (1 × 105 cells) were incubated with 10µg/ml
of full-length IgG or F(ab’)2 fragment (#115-005-075 and #115-
006-02; Jackson ImmunoResearch Laboratories, PA, USA) in
10%FCS/RPMI with the supplement of 1X MEM non-essential
amino acid, 1mM Na pyruvate, 2mM L-glutamine, 10mM
Herpes, 100 u/ml of Pen/Strep, and 0.05mM 2-mercaptoethanol
for 48 h at 37C and 5% CO2. The proliferation of B cells
was examined by the MTS assay followed by the manufacturer
protocol (#G3580, Promega Corporation, Madison, USA).
The viability of B cells was examined after the stimulation
with DMXAA (5,6-Dimethylxanthenone-4-acetic acid or STING
ligand). In brief, B cells (1× 106 cell/ml) were cultured in 6-well-
plates and then stimulated with 10µg/ml DMXAA (Invivogen,
San Diego, USA) and DMSO (control group) for 6 and 24 h at
37◦C and 5% CO2. Then B cells were stained with antibody and
Fixable Viability Dye eFluor R© 780.
CFSE Labeling
CFSE (Carboxyfluorescein succinimidyl ester) labeled B cell
analysis was described using the protocol below. The 1 × 106
B cells in pre-warmed PBS were incubated with 0.5 uM CFSE
(Biolegend, San Diego, CA, USA) in the CO2 incubator at 37
◦C
for 10min. The labeling activity was quenched by adding 10
volumes of culture medium. Then, labeled cells were centrifuged
at 4◦C with a speed of 1,500 rpm for 5min. After centrifugation,
the supernatant was discarded, and cells were re-suspended in the
culture medium.
Statistical Analysis
The sample size of each experiment was calculated by the G-
Power software version 3.1.9.2. The statistical test in this study
was performed with Excel 2016, GraphPad Prism version 5 (for
window), and also Instant Clue software. The data was evaluated
normality by the Shapiro-Wilk test. Independent t-tests were
used in case of the normal distribution; otherwise, the Mann–
WhitneyU-test was applied. The significant statistical change was
considered when P < 0.05. The arthritis scores were analyzed
with multiple comparisons using Friedman’s Two-way Anova for
every time points of all groups, and the results of the comparisons
were statistically significant (P< 0.001).We then performed post-
hoc analysis by the Mann-Whitney correction of all pairwise.
We performed the multiple testing correction using Bonferroni
correction of the P-values.
For the proteomic analysis, protein must be identified at
least three from each mice group (If the protein did not pass
this criterion, the protein must be excluded from downstream
analysis). A hierarchical cluster was used to analysis of heatmap
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FIGURE 1 | STING was not necessary for arthritis development in the CIA model. The mice were injected with CFA or CFA plus chicken collagen type 2 on days 0
and 21. The clinical sign of arthritis and pathology were observed. (A) The representative of hind paws from WT and Stinggt/gt mice, and (B) the cumulative incidence
of arthritis from WT and Stinggt/gt mice are shown. (C,D) Arthritis scores were blindly graded every other day. Data are shown as the median on (C) line chart and (D)
interquartile range (*p < 0.05; a = Mann-Whitney U-test; b = Bonferroni correction; N = 13–14 mice/group). (E) Histopathology of hind paws was stained with H&E;
Scale bar = 100 um. Histology scores were graded with blind technique on three parameters, (F) cell infiltration, (G) synovial hyperplasia, and (H) bone erosion. Data
are shown as mean ± SEM; N = 3 mice/group.
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FIGURE 2 | Immunophenotypes in response to CIA. The samples were collected from WT and Stinggt/gt mice after the 1st immunization with CFA, CFA + CII, or PBS
control for 3 weeks. (A–E) Flow cytometry analysis of inguinal lymph nodes (N = 4–7 per group) are shown in the number of (A) B220+ cells, (B) CD4+ cells, (C)
CD4+CD45RBlow cells, (D) CD11c+B220+ cells (pDC), (E) CD11b+CD11c+ (mDC). (F–I) The serum cytokines of (F) IFN-γ, (G) IL-6, (H) IL-17A, and (I) IL-1α were
measured. Data are shown as mean ± SEM; N = 3–8 mice for PBS control or CFA; N = 10–12 mice for CFA+CII (*p < 0.05, **p < 0.01, and ***p < 0.001).
(Euclidean metric and complete linkage). The heatmap and
volcano plot was operated by Instant Clue software.
RESULTS
Sting Was Not Necessary for Arthritis
Development in the CIA Model
Both WT and Stinggt/gt mice developed clinical arthritis within
Day 42 (6th week) after the initial immunization (Figure 1A).
The accumulative incidence of arthritis was comparable between
WT and Stinggt/gt mice (Figure 1B). We observed that the
Stinggt/gt mice showed a significantly higher value in arthritis
score thanWTmice on Day 29 and 31 (Figures 1C,D). However,
the multiple comparisons by Bonferroni correction did not
demonstrate the difference in arthritis score (adjusted P >
0.05; Figure 1D). The histopathology showed the similarity
in inflammatory cell infiltration, synovium hyperplasia, and
bone erosion between WT and Stinggt/gt mice (Figures 1E–H).
These data suggested that STING was not required for arthritis
development in the CIA model.
Immunophenotypes in Response to CIA
To identify the immunophenotypes that mediated through the
STING signaling pathway, we analyzed the flow cytometry of
the isolated cells from draining lymph nodes (LN) of the mice
after the first immunization for 3 weeks. We found that the
number of B220+ cells (Figure 2A), CD4+ cells (Figure 2B),
CD4+CD45RBlow (Figure 2C), CD11c+B220+ (Figure 2D), and
CD11b+CD11c+ (Figure 2E) were increased in the CFA controls
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FIGURE 3 | The STING-deficient mice developed a higher production of anti-collagen type 2 antibody. The level of anti-collagen type 2 antibodies detecting by the
ELISA technique after the 1st immunization for 3 weeks, and the 2nd immunization for 3 weeks are shown on (A–D). The isotypes of anti-collagen type 2 antibodies in
(A) IgM, (B) IgG, (C) IgG2b, and (D) IgG2c are shown in concentration as mean ± SEM; N = 5 mice/group in CFA control and N = −11 mice/group in CFA+CII
treatment (*p < 0.05 and **p < 0.01).
and CFA+CII treatment compared to PBS injection. These
changes in the LN similarly occurred in both WT and Stinggt/gt
mice. Also, we detected the inflammatory cytokines in the
serum of both WT and Stinggt/gt mice and did not see the
difference in response to the first immunization. The levels
of IFN-γ (Figure 2F), IL-6 (Figure 2G), IL-17A (Figure 2H),
and IL-1α (Figure 2I) increased in both CFA and CFA +
CII. These data suggested the STING did not influence of the
immunophenotypes that responded to the CFA or CFA + CII in
the draining LN and inflammatory cytokines that we tested in
the serum.
The Sting-Deficient Mice Developed Higher
Levels of Anti-collagen Type 2 Antibodies
The arthritis score did not show the statistically significant
between WT and STING-deficient mice when using multiple
corrections (Figure 1D), which could result from the number
of mice in the experiments. However, we observed some of the
STING-deficient mice developed arthritis earlier than WT mice.
Thus, we questioned whether STING might act as a negative
regulator to control the initial process of autoimmune arthritis
in the CIA model.
Anti-collagen type 2 antibodies are pathogenic and mediate
arthritis in the collagen antibody-induced arthritis (CAIA) (29).
We hypothesized that the STING-deficient mice produced the
anti-collagen type 2 (CII) antibodies higher thanWTmice, which
led to the early development of arthritis. The level of anti-CII
antibodies detected by ELISA showed no statistically significant
difference of anti-CII IgM after 3 and 6 weeks of the first and
second injection of CFA and CII (Figure 3A). However, we
detected the significant difference of anti-CII IgG and IgG2c after
3 weeks of CFA and CII injection (Figures 3B,D) while anti-
CII IgG2b slightly showed a trend higher in the STING-deficient
mice (Figure 3C). Interestingly, the anti-CII IgG and isotypes
showed a comparable amount after the second boost with CFA
and CII (Figures 3B,D). These data suggested that STING may
be involved in the initiation of autoantibody production in the
CIA model.
Gene Expression Profiles of Splenocytes in
Response to CIA
To globally identify the biological process that changed in the
immune system after the CIA, we isolated splenocytes from
WT and Stinggt/gt mice after the 1st immunization with CFA
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FIGURE 4 | Gene expression profiles of splenocytes in response to CIA. Gene expression profiles that significantly changed in the isolated splenocytes from WT and
Stinggt/gt mice after the 1st immunization with CFA + CII for 2 weeks were analyzed. (A,B) The heat map shows the genes that significantly changed comparing
(Continued)
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FIGURE 4 | between WT and Stinggt/gt mice (p < 0.05). (A) Data of all of the genes and (B) the interferon signature genes are shown in the sample signal/average
signal (N = 7 mice per group). (C) The bioinformatics analysis of microarray data shows the molecular function of genes that significantly different between WT and
Stinggt/gt mice after the immunization with CFA + CII for 2 weeks.
+ CII for 2 weeks and analyzed gene expression profiles.
The gene expression profiles that were significantly different
between WT and Stinggt/gt mice are shown in the heat map
(Figures 4A,B). The changes in gene expression profiles of
splenocytes included both interferon-inducible genes and non-
related interferons (Figure 4A). Most of the interferon-related
genes were down-regulated in the Stinggt/gt mice (Figure 4B).
These data suggested that the severity of CIA in Stinggt/gt mice
may not directly be related to the interferon signaling pathway.
Next, we analyzed the molecular function of these gene lists.
Interestingly, the biological process related to the signaling by
the B cell receptor (BCR) showed up in the data of isolated
splenocytes (Figure 4C). The lists of biological processes were
shown (Supplementary Table 1). These data pointed out the
potential function of STING signaling in B cell biology.
Sting Negatively Regulates BCR Induced
Cell Proliferation
To identify the function of STING in B cells, we isolated
the B cells from the spleen of immunized mice with CFA +
CII and achieved up to 95% of the purity (Figure 5A). The
viability of the isolated B cells was more than 90% (Figure 5B).
These B cells were subjected to analysis by LC-MS/MS. The
volcano plot shows the proteins that were changed after CFA
+ CII comparing between WT and Stinggt/gt mice (Figure 5C).
The proteins that showed the difference in expression were
analyzed and categorized. The pie chart illustrates the biological
processes that occurred in B cells (Figure 5D). The molecular
functions that changed were B cell proliferation, B cell receptor
signaling, antigen presentation, and death signal (Figure 5D).
The bioinformatics analysis of protein expression in B cells
suggested that STING may be involved in B cell signaling and
B cell proliferation. The lists of biological processes were shown
(Supplementary Table 2).
To test if the B cell signaling mediated through STING,
we stimulated the isolated B cells from the WT and Stinggt/gt
mice that were injected with PBS control, CFA, or CFA + CII
(Figures 5D–G). The B cells from all of the treatments that
were cultured in the regular medium showed no proliferation
(Figure 5E). The anti-IgM stimulated B cells to proliferate in
PBS control and CFA injected groups from both WT and
Stinggt/gt mice measured with MTS assay (Figure 5F). However,
the B cells from the CFA + CII treatment group showed
the difference in MTS fluorescence intensity between WT and
Stinggt/gt mice (Figure 5F). The B cells from Stinggt/gt mice
significantly showed the MTS fluorescence intensity higher than
WT mice (Figure 5F). A similar pattern of B cell response
was detected when stimulated with F(ab’)2 (Figure 5G). The
difference of fluorescence intensity from MTS assay could derive
from the change of proliferation or the viability of B cells. Thus,
we performed the CFSE dilution assay to determine whether
the proliferation or the viability that was mediated by STING
activation in B cells. The stimulation with anti-IgM and F(ab’)2
induced the CFSE dilution assay of B cells isolated fromWT and
Stinggt/gt mice in a similar manner (Figures 5H–J). These data
suggested that STING played a role as a negative regulator of B
cell survival in the stimulated B cells.
Activation of Sting Mediated B Cell Death
Our bioinformatics analysis showed the alteration of the
apoptosis and death pathway that may be related to STING
signaling (Figures 4C, 5D). Also, our data suggested that STING
may affect the survival of B cells (Figures 5F–H). To confirm
that STING can mediate cell death in B cells, the isolated B
cells from the spleen of WT and Stinggt/gt mice were incubated
with DMXAA (STING ligand) and subsequently analyzed by
flow cytometry. The B cells from the mice that were treated
with PBS or CFA + CII did respond to DMXAA in a similar
pattern (Figures 6A,B). The STING activation mediated B cell
death in WT mice but not in Stinggt/gt mice (Figures 6A,B). We
also looked at the mean fluorescence intensity (MFI) of FAS on
B cells and found an increase in FAS expression upon DMXAA
stimulation (Figures 6C,D). These data suggested that STING
mediated B cell death and increased FAS expression in both naïve
and antigenic primed B cells.
The analysis by flow cytometry showed the absence of
FSchiSSchi B cells in WT mice after STING activation, while
Stinggt/gt mice showed the presence of these B cell subsets
(Figure 6E). The quantification of these B cell subsets was shown
(Figure 6I). The activation with DMXAA significantly reduced
the percentage of these FSchiSSchi B cell subsets in WT mice
(Figure 6I). These data suggested that STING mainly targeted
these FSchiSSchi B cell subsets. Next, we determined whether the
absence of these B cell subsets after STING activation inWTmice
resulted from cell death. We detected the percentage of viable
cells in the FSchiSSchi B cells was significantly decreased in WT
mice after STING activation but was preserved in Stinggt/gt mice
(Figures 6J,K). The FSchiSSchi B cells may represent the activated
B cells, which were the preferred target of STING mediated cell
death. Further analysis showed that the number of IAb+ cells
in the FSchiSSchi B subset significantly diminished in WT mice
upon STING activation (Figures 6L,M). The activation of STING
mediated B cell survival was detected in the first 6 h as well
(Supplementary Figure 1).
Next, we confirmed that STING mediated B cell death was
targeted at the activated B cell by staining CD80 (a costimulatory
molecule) and IAb (MHC-II) as a marker of the activated B cells.
The MFI of IAb and percentage of CD80+ B cells significantly
increased in the DMXAA activated WT B cells compared to
Stinggt/gt B cells (Figures 6N,O,R,S). Also, the percentage of
dead cells in IAb+ B cells and CD80+ B cells significantly
increased inWT B cells but not in Stinggt/gt B cells after DMXAA
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FIGURE 5 | STING negatively regulates B cell survival. Isolated B cells from the spleens of immunized mice (WT and Stinggt/gt ) with CFA+CII were analyzed by
LC-MS/MS (A–D). (A) The isolation of B cells shown up to 95% of purity, and (B) the B cells had 94% viability that was subjected to B cell functional study. (C) The
(Continued)
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FIGURE 5 | data from LC-MS/MS experiment shown in the volcano plot (N = 6 samples per group, and each sample consist of 2 mice; p < 0.05). (D) The pie chart
shows the bioinformatics analysis of the proteins that characterized the molecular functional groups. (E–J) Isolated B cells from the spleens of WT and Stinggt/gt mice
after the injection with PBS, CFA, or CFA + CII were incubated with (E) culture medium, (F) anti-IgM, and (G) F(ab’)2 for 48 h then measured the cell viability by the
MTS assay. (H–J) CFSE dilution assay of B cells after stimulation with anti-IgM, and F(ab’)2 to determine the proliferation. (H) The mean fluorescence intensity (MFI) of
CFSE labeling B cells are shown as mean ± SEM; N = 3–4 mice/group (*p < 0.05). The representative histograms of CFSE labeling B cells isolated from WT and
Stinggt/gt mice after stimulation with (I) anti-IgM and (J) F(ab’)2 are shown.
stimulation (Figures 6P,Q,T,U). These results suggested that
STING activated B cell death.
DISCUSSION
Collagen-Induced arthritis (CIA) model has similar features
with rheumatoid arthritis (30). The immunization with complete
Freund’s adjuvant (CFA) and collagen type 2 induces the
production of anti-collagen type 2 antibody, rheumatoid factor
(RF), and anti-cyclic citrullinated peptide antibodies (anti-
CCP) (30). The scores of arthritis in the Stinggt/gt mice that
were comparable to WT mice in this study were unexpected.
We detected the significant reduction of CD11c+B220+ and
CD11b+CD11c+ cells in the Stinggt/gt mice after the CIA,
which may suggest that STING functioned in the promotion
of dendritic cells. However, the differnce of antigen-presenting
cells (APC) between WT and Stinggt/gt mice did not explain the
similarity in arthritis phenotypes of both WT and Stinggt/gt mice
in the CIA.
The adaptive immunity is crucial for CIA development. The
CD4-deficient mice are less susceptible to the CIA thanWTmice
(31). Th17 cells were shown as one of the significant players
of the CIA (32). The IFN-γ knockout mice increase the Th17
cells which accelerate the CIA (33). STING activation in T cells
induces the production of IFN-I and IFN-γ (34). However, the
Stinggt/gt and WT mice showed a similar pattern of serum IFN-γ
and IL-17 in response to the CIA. Also, our study did not detect
the difference in T cell phenotypes between WT and Stinggt/gt
mice. The data suggested that the difference in arthritis between
WT and Stinggt/gt mice did not contribute by T cell alteration.
The B cells are required for CIA development (35). The rise of
anti-collagen type 2 antibody in the early phase in the Stinggt/gt
mice, before the second immunization, suggested the increase
of B cell activity in the Stinggt/gt mice. Although the severity of
arthritis was caught up withWTmice at week 6, this finding may
be explained by the fact that the levels of anti-collagen type 2
antibody were boosted after the second immunization with CFA
and CII. Interestingly, the analysis of gene expression profiles
from splenocytes at the early phase after the first immunization
suggested the increase in B cell signaling. Also, the expression
of interferon-inducible genes decreased in the Stinggt/gt mice
compared with WT after the CIA. The administration of IFN-
β into the CIA mice reduced inflammation and slow cartilage
destruction (36). The combination of the increase of B cell
activity and the decrease in IFN-I function may promote arthritis
development in the Stinggt/gt mice.
The function of STING in B cells showed different
results. The expression of STING on B cell is required for
antibody response to T cell-dependent antigens and cyclic-di-
GMP (CDG) (37). The activation of STING with CDG acts
synergistically with B cell receptors to increase the expression
of co-stimulatory molecules (CD86) (37). The STING-deficient
MRL/lpr mice developed severe autoimmunity with an increase
in autoantibody production (24). Another study shows that
STING negatively regulates dsDNA-activated JAK1-STAT1 via
SHP-1/2 in B cells (38). SHP-1 is a protein-tyrosine phosphatase
that dephosphorylates the proximal BCR signaling or mediates
the function of certain inhibitory ITIM containing receptors (39).
The deletion of SHP-1 in B cells leads to systemic autoimmunity
(40). Here, we detected the increase of B cell survival in the
Stinggt/gt mice upon BCR engagement with anti-IgM and F(ab’)2,
especially in the isolated B cells from mice that were immunized
with CFA and collagen type 2.
The CD43− B cells are immature follicular B cells (41).
In theory, these populations should not be different between
immunized or non-immunized mice. Our data showed the
difference in BCR response of CD43− B cells from the
immunized group (CFA+CII) of STING-deficient mice.
However, the CD43 (or S7) negative cells upregulate the
expression of CD43 after LPS stimulation (42). Due to the CD43
negative selection it is possible that antigen specific B cells in
our in vitro experiments only comprised a fraction of all antigen
activated B cells. These data suggested that STING worked as a
negative regulator for BCR signaling in the stimulated B cells.
The proteomics data of B cells showed the increase of several
proteins involved in apoptosis and death signals. Activation of
STING induces apoptosis in malignant B cells (43). We found
that STING ligand-induced B cell death, which broadly affected
either naïve or stimulated B cells. The flow cytometry showed
that the preferentially targeted B cells for STING induced cell
death were the activated B cells (IAb+FSChiSSchi, or CD80+).
Thus, the absence of STING in B cells maintained the activated
B cell to survive and allowed the stimulated B cells to respond
to the signaling from BCR, which subsequently augmented the
antibody production and antigenic presentation.
In summary, DNA sensing through the STING pathway
activates innate immunity and induces inflammation (19). Our
study demonstrated that STING promoted the expression of
IFN-inducible genes and dendritic cell expansion in the CIA.
At the same time, STING functioned as a negative regulator in
the B cells upon BCR engagement, a mechanism that controls
the hyperactivation of B cells. STING-deficient mice do not
spontaneously develop autoimmune diseases (44). These data
suggested the STING worked differently in a particular cell type
with a specific stimulation. The counter-regulatory function of
STING in the adaptive immunity could keep the balance between
inflammation and tolerance.
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FIGURE 6 | Activation of STING mediated B cell death. The isolated B cells from the spleens of immunized mice (WT and Stinggt/gt ) were cultured with DMSO control
or DMXAA for 24 h and analyzed by flow cytometry. (A,B) Percentage of B cell viability of (A) PBS and (B) CFA+CII injection group. (C,D) Mean fluorescence intensity
(Continued)
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FIGURE 6 | (MFI) of FAS on B cells from (A) PBS and (B) CFA+CII injection group. (E–H) Representative plots from the PBS injection group show FSC and SSc. The
gated areas show the FSchiSSchi B cells population. The isolated B cells from WT and Stinggt/gt mice were cultured with (E,G) DMSO and (F,H) DMXAA. (I) Data
showed the percentage of FSchiSSchi B cells isolated from the immunized WT and Stinggt/gt mice after incubation with DMSO and DMXAA. (J–U) Flow cytometry
analysis showed (J,K) the percentage of viable cells in FSchiSSchi B cells and (L,M) the number of IAb+FSchiSSchi B cells from the mice injected with PBS and
CFA+CII. (N,O) Mean fluorescence intensity (MFI) of IAb+ on B cells from (N) PBS and (O) CFA + CII injection group. (P,Q) Percentage of dead IAb+ B cells of the
mice injected with (P) PBS and (Q) CFA + CII. (R,S) Percentage of CD80+ B cell from (R) PBS and (S) CFA+CII injection group. (T,U) Percentage of dead CD80+ B
cells of the mice injected with (T) PBS and (U) CFA+CII. Data are shown as mean ± SEM; N = 3-6 mice/group (*p < 0.05, **p < 0.01, and ***p < 0.001).
CONCLUSION
Inhibition of STING in B cells promoted the activated B cell
survival in the CIA model.
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